close

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Its products under development include Zerenex, an oral iron-based compound is in Phase II clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease in the United States and Japan; and KRX-0401, an oral anti-cancer agent in Phase II clinical development that modulates Akt, and various other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Keryx Biopharmaceuticals has strategic alliances with AEterna Zentaris Inc.; Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. for the manufacture and commercialization of its products. The company was formerly known as Lakaro Biopharmaceuticals, Inc. and changed its name to Keryx Biopharmaceuticals, Inc. in January 2000. Keryx Biopharmaceuticals, Inc. was founded in 1998 and is based in New York, New York.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	4.08
Volume	(mio) 1.59
Volume Avg	(mio) 1.93
52 Week High	5.55
52 Week Low	2.27
PE	N/A
PE (group average)	39
EPS Year	-0.42
EPS change Q/Q	-11.11%
EPS change Q/Q Yr ago	-42.86%
EPS change Q/Q next Q est	-16.67%
EPS change Y/Y	-1000%
REV change Q/Q	0%
REV change Q/Q Yr ago	0%
EPS next Q est	-0.12
EPS next Y est	0.53
Divident Annual	0.00
Dividend Yield	0%